Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H22F2N2O3S |
| Molecular Weight | 420.473 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C=C(C2CCN(C)CC2)C3=C1C=CC(OS(=O)(=O)C4=C(F)C=CC=C4F)=C3
InChI
InChIKey=LYHNZWIPSZUYDT-UHFFFAOYSA-N
InChI=1S/C21H22F2N2O3S/c1-24-10-8-14(9-11-24)17-13-25(2)20-7-6-15(12-16(17)20)28-29(26,27)21-18(22)4-3-5-19(21)23/h3-7,12-14H,8-11H2,1-2H3
| Molecular Formula | C21H22F2N2O3S |
| Molecular Weight | 420.473 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
SGS518 is a selective antagonist of the 5-Hydroxytryptamine-6 (5-HT6) serotonin receptor believed to act by enhancing transmission of chemicals in the brain. Prior preclinical evaluation of SGS518 has shown it to be effective in behavioral studies of learning and memory. Saegis is developing SGS518 in cooperation with Eli Lilly and Company as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS) with some support from The Stanley Medical Research Institute. SGS518 in the phase II of clinical trial. The objective of this Phase IIa study was to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral doses of SGS518 compared to placebo when given to schizophrenia patients stable on antipsychotic medication. SGS518 appears to be safe and well tolerated with preliminary evidence suggesting improvement in cognition using the BACS in patients with schizophrenia.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:27:53 GMT 2023
by
admin
on
Sat Dec 16 07:27:53 GMT 2023
|
| Record UNII |
97S8606IT3
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6918827
Created by
admin on Sat Dec 16 07:27:53 GMT 2023 , Edited by admin on Sat Dec 16 07:27:53 GMT 2023
|
PRIMARY | |||
|
445441-26-9
Created by
admin on Sat Dec 16 07:27:53 GMT 2023 , Edited by admin on Sat Dec 16 07:27:53 GMT 2023
|
PRIMARY | |||
|
97S8606IT3
Created by
admin on Sat Dec 16 07:27:53 GMT 2023 , Edited by admin on Sat Dec 16 07:27:53 GMT 2023
|
PRIMARY | |||
|
DTXSID20196217
Created by
admin on Sat Dec 16 07:27:53 GMT 2023 , Edited by admin on Sat Dec 16 07:27:53 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
